博瑞医药(688166) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥271,971,006.83, representing a year-over-year increase of 0.99%[5] - Net profit attributable to shareholders for Q3 2022 was ¥85,622,530.05, an increase of 22.31% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥86,260,922.43, up 24.09% year-over-year[5] - The basic earnings per share for Q3 2022 was ¥0.21, reflecting a 23.53% increase year-over-year[5] - For the first nine months of 2022, the company achieved operating revenue of RMB 772.32 million, a year-on-year increase of 3.19%[15] - The net profit attributable to shareholders for the same period was RMB 197.62 million, reflecting a year-on-year growth of 11.73%[15] - In Q3 2022, the company's operating revenue grew by 0.99% year-on-year, while the net profit attributable to shareholders increased by 22.31%[15] - Total operating revenue for the first three quarters of 2022 reached ¥772,321,355.75, an increase from ¥748,440,872.31 in the same period of 2021, representing a growth of approximately 3.7%[30] - Net profit for the third quarter of 2022 was ¥177,878,679.31, slightly up from ¥170,780,575.00 in the previous year, reflecting a growth of approximately 4.1%[34] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥4,086,290,770.81, a 37.60% increase from the end of the previous year[7] - The company's total liabilities amounted to ¥2,073,869,767.97, a significant increase from ¥1,227,980,082.88 in the previous period, marking a rise of about 69%[28] - The total equity attributable to shareholders reached ¥2,012,421,002.84, up from ¥1,741,634,980.86, which is an increase of approximately 15.5%[29] - The total liabilities and equity amounted to ¥4,086,290,770.81, up from ¥2,969,615,063.74, reflecting an increase of about 37.8%[29] Research and Development - R&D investment totaled ¥45,204,654.13 in Q3 2022, accounting for 16.62% of revenue, an increase of 1.60 percentage points from the previous year[7] - The company submitted 8 domestic patent applications and 2 foreign patent applications in Q3 2022, with a total of 356 patent applications filed to date[18] - Research and development expenses for the first three quarters of 2022 were ¥139,053,362.88, compared to ¥119,784,659.32 in 2021, showing an increase of about 16.0%[30] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥205,840,314.51, a significant increase of 149.28%[9] - Operating cash inflow for the first three quarters of 2022 reached RMB 922,221,335.76, an increase of 35.5% compared to RMB 680,266,726.68 in the same period of 2021[40] - Net cash flow from operating activities was RMB 205,840,314.51, up from RMB 82,574,695.65 in the previous year, representing a significant increase of 149.5%[40] - Cash inflow from investment activities totaled RMB 549,372,292.79, compared to RMB 312,232,702.80 in the previous year, marking a rise of 75.9%[41] - Net cash flow from investment activities was -RMB 793,963,854.22, worsening from -RMB 659,665,113.77 year-on-year[41] - Cash inflow from financing activities amounted to RMB 1,379,052,375.62, significantly higher than RMB 718,183,266.13 in the same period last year, an increase of 92%[41] - Net cash flow from financing activities was RMB 883,781,300.36, compared to RMB 553,064,914.12 in the previous year, reflecting a growth of 59.8%[41] - The company reported a net increase in cash and cash equivalents of RMB 300,184,511.17, contrasting with a decrease of RMB 22,123,636.36 in the same period of 2021[41] - The ending balance of cash and cash equivalents stood at RMB 633,399,193.09, up from RMB 317,409,878.26 year-on-year, indicating a growth of 99.5%[41] Government Subsidies and Tax Refunds - The company reported a total of ¥5,233,779.87 in government subsidies recognized in Q3 2022[8] - The company received RMB 75,465,505.99 in tax refunds, which is a 132.5% increase from RMB 32,462,495.74 in the previous year[40] Production and Capacity Expansion - The company has completed construction and verification of its first-phase raw material and formulation production base in Taixing[19] - The company has received drug clinical trial approval for BGC1201 tablets and marketing application approval for a raw material drug[16] - The company is in the process of expanding its production capacity with multiple projects, including the Suzhou high-end formulation drug production project[19]